ML20198K256

Forwards Application for Amend to License DPR-63.Amend Would Delete License Condition C(4) & License Page 3B from License & Delete Requirement to Maintain Potassium Iodide Tablets at Facility

ML20198K256
Person / Time
Site:	Nine Mile Point
Issue date:	12/18/1998
From:	Mueller J NIAGARA MOHAWK POWER CORP.
To:	NRC OFFICE OF INFORMATION RESOURCES MANAGEMENT (IRM)
Shared Package
ML20198K260	List: ML20198K256 ML20198K263
References
NMP1L-1394, NUDOCS 9812300391
Download: ML20198K256 (2)

Text

_

j NiagarahMohawk' John H. Muelle' Phone: 315.349.7907 Senior Vice President and Fax: 31s.34g.1321 ChielNuclear Officer e-mail: muelleri@nimo.com December 18, 1998 NMPIL 1394 U. S. Nuclear Regulatory Commission Attn: Document Control Desk Washington, DC 20555 RE:

Nine Mile Point Unit 1 Docket No. 50-220 DPR-63 Gentlemen:

Niagara Mohawk Power Corporation (NMPC) hereby transmits an Application for Amendment to the Nine Mile Point Unit 1 (NMP1) Operating License, DPR-63. Enclosed as Attachment A is the proposed change to the NMP1 Operating License. Supporting information and analyses pursuant to 10 CFR 50.92 which demonstrate that the proposed change does not involve a significant hazards consideration is included as Attachment B.

The basis for concluding that this application meets the criteria of 10CFR51.22 for categorical exclusion from performing an environmental assessment is included as Attachment C. To assist the NRC Staff with their review, a hand marked-up copy of the proposed change is provided as Attachment D.

The proposed change deletes license condition C(4) and license page 3B from the Operating License and deletes the requirement to maintain potassium iodide tablets at NMP1. NMPC committed to provide information demonstrating compliance with GDC-19 dose guidelines for the NMP1 Control Room in its letter dated May 23,1998 (NMP1 L 1323). In a letter dated March 19,1984, NMPC prov:'ed its response to NUREG-0737, item Ill.D.3.4, regarding NMP1 Control Room habitability. The 1984 submittal provides the base assumptions for the analyses and is the licensing basis for NMP1. Attachment E summarizes the assumptions and the results of updated analyses performed consistent with NMPC's 1984 response to NUREG-0737, item Ill.D.3.4. The analyses have been reperformed using a different computer code, which provided comparable results to that of the previous code. The results of the analyses demonstrate that the use of potassium iodide tablets is not required as a means to satisfy GDC-19 dose guidelines. Since the information requested by the license condition is included in Attachment E and is, therefore satisfied, this license condition and the requirement to maintain potassium iodide tablets are no longer needed.

T' S r

)

[k. SQ g\\

9812300391 981218 O

PDR ADOCK 05000220,'

P PDR Nine Mile Point Nuclear Station RO. Box 63, Lycoming, New York 13093-0063

. _. _ _.. -.. _... ~ _

i l

l Page 2 i

Pursuant to 10CFR50.91(b)(1), NMPC has provided a copy of this license amendment L-application and the essociated analysis regarding no significant hazards consideration to i

the appropriate state representative.

Very truly yours, i

i hn H. Mueller Senior Vice President and l

Chief Nuclear Officer JHM/TWP/ kap.

Attachments xc:

Mr. H. J. Miller, NRC Regional Adntinistrator, Region 1 Mr. S. S. Bajwa, Director, Project Directorate,1-1, NRR Mr. G. K. Hunegs, Senior Resident inspector Mr. D. S. Hood, Senior Project Manager, NRR Mr. J. P. Spath NYSERDA l

286 Washington Avenue Ext.

Albany, NY 12203-6399 Records Management r

l-i l-

--.